Abstract. Biomarkers that facilitate the prediction of breast cancer prognosis can improve the quality of life in patients during the long period of illness and treatment. Particularly in recent years, with the advent of a more exhaustive analysis of genetic information and gene products, the molecular mechanisms at play during breast cancer have gradually become clearer. In the present study, a systematic review of the literature between 2009 and 2014 was conducted by searching for the keywords ‘breast cancer’, ‘biomarkers’, ‘diagnosis’, ‘prognosis’ and ‘drug response’ to clarify the present state of knowledge regarding biomarkers. In the final analysis, 16 studies on biomarkers for the breast cancer prognosis were retrieved. From these, 7 biomarkers in 9 studies were found to be strongly reliable predictors of prognosis and a further 7 biomarkers in 7 studies were poorly reliable. The use of these prognostic biomarkers should increase the options available for treatment algorithms.

Contents
1. Introduction
2. Literature search
3. Highly reliable biomarkers (Table I)
4. Low and moderately reliable biomarkers (Table II)
5. Conclusions

1. Introduction

Currently, breast cancer treatment is progressing on a daily basis, and is divided into subtypes based on the hormone receptors human epidermal growth factor receptor type 2 (HER2) and Ki-67 (1). However, treatment algorithms do not necessarily result in satisfactory clinical outcomes. Therefore, to further improve the breast cancer prognosis, predictive factors are required in order to arrive at more accurate prognoses and improve treatment efficacy. If such biomarkers could be identified, it would be possible to provide appropriate treatments to relevant subjects, resulting in excellent clinical outcomes. To date, prognostic prediction has been based on older studies of morphological characteristics (2). More recent research has concentrated on molecular biomarkers (3). The present study reports the findings of a systematic review of prognosis for patients with breast cancer based on molecular biomarkers. The correlations between these biomarkers, prognosis and the treatment response may be useful for all breast cancer patients.

2. Literature search

A search of the PubMed database (National Center for Biotechnology Information, Bethesda, MD, UDA) using the key words ‘breast cancer,’ ‘biomarkers,’ ‘diagnosis,’ ‘prognosis’ and ‘drug response’ retrieved 1,689 potential studies. Subsequent to filtering for studies involving humans and written in English, 76 studies were excluded. When the remaining reports were limited to the period between 2009 and 2014, an additional 688 were excluded. Of the remainder, 520 studies were excluded, as they did not contain the full text. Finally, the abstracts of 405 studies were evaluated and those that contained insufficient descriptions of diagnostic performance, prognosis and drug response were excluded, resulting in a total of 16 studies for analysis (Fig. 1).

3. Highly reliable biomarkers (Table I)

Retinoic acid receptor α (RARA). Approximately 1/3 of estrogen receptor α (ERα)-positive breast cancer patients treated with tamoxifen experienced a relapse of the disease (4). RARA is a potential biomarker for tamoxifen resistance (5). The anti-tumor properties of RARA can be explained in association with the interaction of the receptor with ERα and their joint genomic binding site (6). The association between ERα resistance and RARA resistance was confirmed using tamoxifen-susceptible and -resistant cell lines (MCF7 and
LCC2, respectively). The tamoxifen-resistant cells were found to express high levels of RARA (7).

Patients with ERα-positive breast cancer tumors with high internal levels of RARA protein that were treated with tamoxifen as adjuvant therapy exhibited shorter recurrence-free survival (RFS) than patients with low internal levels of RARA protein (7). Johansson et al (7) performed an investigation into serum RARA levels using ELISA, and found significantly higher RFS rates in patients with high RARA expression levels compared with patients with low levels: Hazard ratio (HR)=4.1; 95% confidence interval (CI)=1.55-11.0; P=0.0046. Therefore, RARA may potentially be a useful target of new treatment regimens and a biomarker to predict the effectiveness of tamoxifen adjuvant treatment in ERα-positive breast cancer.

**Aromatase expression.** Aromatase expression by breast cancer cells has been shown to influence the effectiveness of endocrine treatments for breast cancer (8,9). Ellis et al (10) conducted a study using a sample from a clinical trial comparing tamoxifen and letrozole as neoadjuvant endocrine therapies, and found that aromatase expression levels in tumor and somatic cells was correlated with treatment-induced changes in Ki-67, RFS, and breast cancer-specific survival (BCSS) (11-13).

Aromatase expression was correlated with a smaller tumor size (P=0.01), a higher Allred score of estrogen receptor (P=0.006) (14) and lower Ki-67 levels (P=0.003). In addition, aromatase expression by tumor cells was a significant prognostic factor of the independent variables RFS (HR=2.3; 95% CI=1.2-4.6; P=0.01) and BCSS (HR=3.76; 95% CI=1.4-10.0; P=0.008) (15). The aforementioned data supports the use of aromatase blockers as the first choice treatment for post-menopausal, hormone-positive breast cancer.

**Osteopontin.** Osteopontin is a secreted extracellular matrix adhesion protein associated with tumor cell invasion and metastasis (16,17). Pang et al (18) examined the clinical and pathological effects of the adhesion molecules osteopontin-c, E-cadherin and β-catenin in breast cancer, and found higher expression levels of all the aforementioned adhesion molecules in breast cancer compared with normal tissue. The expression of osteopontin-c was associated with lymph node metastasis, and higher tumor node-metastasis classification (19) and histological grade (19). In addition, high expression levels of osteopontin-c have been correlated with tumor recurrence and metastasis, as well as triple negative subtypes, which are predictive factors of the independent variables disease-free survival (DFS; HR=3.094; 95% CI, 1.229-7.789; P=0.016) and overall survival (OS; HR=2.588; 95% CI, 1.048-6.243; P=0.039) (20). Therefore, the development of treatments targeting osteopontin-c may be beneficial for the treatment of breast cancer.

Ki-67. Ohno et al (21) examined the role of Ki-67 as a predictive biomarker of treatment response in a randomized, multicenter study to compare the effectiveness of docetaxel subsequent to treatment with fluorouracil/epirubicin/cyclophosphamide with or without capecitabine, in patients with operable breast cancer. The endpoint was the rate of pathological complete response (pCR). Analysis of hormone receptors and the Ki-67 labeling index (Ki-67LI) by multivariate logistic regression analysis identified Ki-67 as an independent prognostic factor (HR=2.718; 95% CI=1.331-5.549; P=0.0061). In addition, the aforementioned results also suggest that the Ki-67LI prior to treatment was a predictor for the response to neoadjuvant docetaxel treatment and neoadjuvant capecitabine treatment in early-stage breast cancer.

Denkert et al (22) obtained 1,166 breast cancer bioassay specimens from a large-scale cohort study established to investigate neoadjuvant treatment (the GeparTrio trial) and evaluated pre-treatment Ki-67 levels by immunohistochemical analysis. The study used the standardized, 3-endpoint, cut-off algorithm (pCR, DFS and OS) (23). The Ki-67 index and preoperative chemotherapy variables were divided into 3 subgroups each: ≤15, 15.1-35 and ≥35%, and pCR rates were 4.2, 12.8 and 29.0%, respectively (P<0.0005). The HR for prognosis also increased in response to Ki-67 (HR=1, 3.32 and 9.20, respectively), indicating that Ki-67 is a prognostic predictor for hormone receptor-positive, but not triple-negative, breast cancer. The aforementioned findings regarding Ki-67 may provide important information for the development of other quantitative biomarkers.

DeCensi et al (24) examined postoperative remission and prognosis in response to Ki-67 in early stage ERα-positive breast cancer patients treated with tamoxifen for 4 weeks as a short-term neo-adjuvant therapy and reported that post-treatment levels of Ki-67 in the second (14-19%), third (20-29%), and top (≥30%) quartiles had recurrence HRs of 2.92 (95% CI, 0.95-8.96), 4.37 (1.56-12.25) and 6.05 (2.07-17.65), respectively. The aforementioned data supports the use of aromatase blockers as the first choice treatment for post-menopausal, hormone-positive breast cancer.
Table I. List of biomarkers that presented ≥2 risk ratios compared with the control populations (high reliable markers).

<table>
<thead>
<tr>
<th>Authors</th>
<th>Biomarker</th>
<th>Endpoint</th>
<th>Condition</th>
<th>HR</th>
<th>95% CI</th>
<th>No.</th>
<th>Sample</th>
<th>Periods</th>
<th>(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>High RARA</td>
<td>4.1</td>
<td>1.55-11.0 (P=0.046)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellis et al</td>
<td>Aromatase</td>
<td>BCSS</td>
<td>Absent</td>
<td>1.0</td>
<td>-</td>
<td>169</td>
<td>Biopsy</td>
<td>1998-1999</td>
<td>(15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Present</td>
<td>3.76</td>
<td>1.4-10.0 (P=0.008)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pang et al</td>
<td>Osteopontin</td>
<td>DFS</td>
<td>Low</td>
<td>1.0</td>
<td>-</td>
<td>200</td>
<td>Biopsy</td>
<td>2002</td>
<td>(18)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>3.094</td>
<td>1.229-7.789 (P=0.016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OS</td>
<td>Low</td>
<td>1.0</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>2.558</td>
<td>1.048-6.243 (P=0.039)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ohno et al</td>
<td>Ki-67</td>
<td>pCR</td>
<td>&lt;10</td>
<td>1.0</td>
<td>-</td>
<td>504</td>
<td>Biopsy</td>
<td>2002-2004</td>
<td>(21)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥10</td>
<td>2.718</td>
<td>1.331-5.549 (P=0.0061)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denkert et al</td>
<td>Ki-67</td>
<td>pCR</td>
<td>0-15%</td>
<td>1.0</td>
<td>-</td>
<td>1,166</td>
<td>Biopsy</td>
<td>2002-2005</td>
<td>(22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;35%</td>
<td>3.2</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;35%</td>
<td>9.2</td>
<td>- (P=0.00005)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DeCensi et al</td>
<td>Ki-67</td>
<td>OS</td>
<td>Pre-tamoxifen &lt;20</td>
<td>1.0</td>
<td>-</td>
<td>86</td>
<td>Biopsy</td>
<td>2004-2007</td>
<td>(24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥20</td>
<td>3.66</td>
<td>0.81-16.47 (P=0.128)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Post-tamoxifen &lt;20</td>
<td>1.0</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥20</td>
<td>5.50</td>
<td>1.26-23.16 (P=0.006)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tsang et al</td>
<td>CEACAM6</td>
<td>OS</td>
<td>CEACAM6 (-)</td>
<td>1.0</td>
<td>-</td>
<td>312</td>
<td>Biopsy</td>
<td>2003-2009</td>
<td>(28)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CEACAM6 (+)</td>
<td>4.107</td>
<td>1.478-11.417 (P=0.007)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cizkova et al</td>
<td>PIK3CA</td>
<td>DFS</td>
<td>Wild type</td>
<td>1.0</td>
<td>-</td>
<td>80</td>
<td>Biopsy</td>
<td>2007</td>
<td>(31)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mutant type</td>
<td>4.26</td>
<td>1.4-13 (P=0.0063)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhu et al</td>
<td>TIMP-</td>
<td>DFS</td>
<td>Low</td>
<td>1.0</td>
<td>-</td>
<td>99</td>
<td>Biopsy</td>
<td>2008</td>
<td>(36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>3.085</td>
<td>1.096-8.680 (P=0.033)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OS</td>
<td>Low</td>
<td>1.0</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>12.907</td>
<td>1.499-111.2 (P=0.020)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RARA, Retinoic acid receptor α; RFS, recurrence-free survival; BCSS, breast cancer-specific survival; pCR, pathological complete response; CEACAM6, Carcinoembryonic antigen-related cell adhesion molecule 6; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase; catalytic subunit α; TIMP-1, Tissue inhibitor of metalloproteinases-1; DFS, disease free survival; OS, overall survival.
respectively, compared with those in the bottom quartile (<14%; P=0.001). The mortality risks were 5.5-fold higher when Ki-67 levels were ≥20% (95% CI=1.26-23.16; P=0.006) when compared to those with Ki-67 levels <20% (P=0.006). The authors concluded that the level of Ki-67 subsequent to short-term neoadjuvant tamoxifen is a good predictor of RFS and OS, supporting the use of Ki-67 as a surrogate biomarker to personalize adjuvant treatment and to cost-effectively screen novel drugs.

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6). CEACAM6 is a human carcinoembryonic antigen that functions as a multi-functional regulatory protein and is overexpressed in various cell processes associated with cancer (25,26). CEACAM6 expression in atypical ductal hyperplasia has been suggested to serve an important role in the development of breast cancer (27). CEACAM6 has also been associated with invasive and treatment-resistant breast cancer (28). However, in a large-scale cohort study, CEACAM6 expression in luminal breast cancer exhibited no effect on OS or correlation with prognosis, although an association between CEACAM6 expression and prognosis in breast cancer overexpressing HER2 was revealed, as the high expression group tended to exhibit poorer OS (28). The aforementioned results indicate that treatment is required for breast cancer patients with HER2 overexpression and the presence of CEACAM6.

Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α (PIK3CA). PIK3CA is a cancer gene coding for 1 of 2 phosphoinositide 3-kinase (PI3 K) subunits (29), which is a gain-of-function mutation in certain types of cancer, and is present in 20-40% patients with breast cancer (30). Cizkova et al (31) identified PIK3CA mutations in 17 (21.3%) tumors among 80 HER2-positive patients treated with trastuzumab for 1 year. Patients exhibiting wild-type PIK3CA demonstrated an improved DFS compared with patients exhibiting the PIK3CA mutations. The prognosis for HER2-positive patients with PIK3CA mutations treated with trastuzumab was significantly worse than for patients exhibiting the wild-type variation, which is considered to occur since the PI3K/protein kinase B pathway is adversely affected by PIK3CA mutations, resulting in the lower efficacy of trastuzumab. Thus, the detection of PIK3CA mutations is only required in HER2-positive patients.

Tissue inhibitor of metalloproteinases-1 (TIMP-1). Paclitaxel is the first chemotherapy treatment of choice for patients with lymph node metastasis (32,33). However, there are currently no biomarkers to predict susceptibility to chemotherapy. TIMP-1 has been shown to protect cells from apoptosis (34). A previous epidemiological study demonstrated an association between high levels of TIMP-1 and reduced responsiveness to cyclophosphamide/methotrexate/5-fluorouracil and anthracycline-based chemotherapy regimens (35).

In a retrospective study of 99 breast cancer patients, Zhu et al (36) reported a correlation between TIMP-1 expression levels in primary tumors and improved responsiveness to paclitaxel-based chemotherapy. Kaplan-Meier survival analysis revealed that patients with high TIMP-1 levels had poorer 5-year DFS that those with lower TIMP-1 levels (71.1 vs. 88.5%, respectively; P=0.020). The 5-year OS was also lower (78.9 and 96.7%, respectively, P=0.004). The responsiveness to paclitaxel-based chemotherapy was significantly worse when the TIMP-1 expression levels were high. The aforementioned findings indicate that TIMP-1 may be a useful predictive biomarker for chemotherapy resistance.

4. Low and moderately reliable biomarkers (Table II)

Ferritin light chain (FTL). Ferritin is a ubiquitous iron-binding protein. In vertebrates, there are 2 types of apoferritin, which are assembled from 24 subunits including light and heavy chain types. The ratio between the ferritin heavy chain and FTL can vary greatly, depending on the tissue type and cellular conditions (37). The increase in ferritin from different cancer tissue samples exhibited a close correlation with disease onset (38). Ricolleau et al (39) investigated the utility of FTL as a prognostic marker for lymph node metastasis-positive breast cancer and determined an FTL cut-off level in tumors of 2.4. The high FTL level group had a significantly lower metastasis-free survival rate, indicating that FTL was an independent prognostic marker (HR=1.30; 95% CI=1.10-1.50; P=0.001) (40).

Urokinase-type plasminogen activator (uPA) and plasminogen activator type 1 inhibitor (PAI-1). uPA, as a tumor-associated proteolytic factor, and PAI-1 serve important roles in tumor invasion and metastasis (41), and cell signaling, adhesion, migration and proliferation (42). In the final Chemo-N0 trial for the validation of The American Society of Clinical Oncology-recommended biomarkers (1993-1998; n=647; 12 centers; median follow-up period 113 months; range between 5 and 167 months), high uPA/PAI-1 levels were correlated with significantly lower DFS among breast cancer patients who did not receive adjuvant treatment (HR=1.84; 95% CI=1.1-3.0; P=0.017) and OS (HR=1.84; 95% CI=1.1-3.1; P=0.02). uPA/PAI-1 was also identified as a prognostic factor for breast cancer in other studies (43).

C-reactive protein (CRP). Serum CRP is a marker of acute inflammatory response and is considered to be a prognostic indicator in breast cancer (44,45). The Women’s Healthy Eating and Living study was a randomized comparative study examining the effect of a diet high in vegetables and low in fat on the prevention of premature mortality in women diagnosed with breast cancer. Serum protein analysis of 2,023 short-term neoadjuvant tamoxifen is a good predictor of RFS and OS. The aforementioned findings indicate that TIMP-1 may be a useful predictive biomarker for chemotherapy resistance.

Chromosome 17 centromere enumeration probe (Ch17CEP). Chromosome 17 is the second densest chromosome in the human genome and codes for several genes, including BRCA1 and HER2 with important roles in breast cancer, as well as the housekeeping DNA repair genes TP53, RAD51C and RAD52B (47). Ch17 centromeric region duplication (Ch17CEP) is closely associated with HER2 amplification (48). Ch17CEP
overlap is also a powerful marker for genome instability in breast cancer and is correlated with susceptibility to chemotherapy (48,49). In novel endovascular access trial/BR9601 clinical trials, prognostic factors were analyzed and categorized according to breast cancer subtype. Although numerous factors were not associated with subtype, Ch17CEP overlap was an independent prognostic factor for DFS and OS for all subtypes. Ch17CEP overlap was identified as a prognostic biomarker for breast cancer treated with cyclophosphamide, methotrexate and fluorouracil therapy in combination with epirubicin (HR=0.80; 95% CI=0.68‑0.95; P=0.009) (50).

Soluble human epidermal growth factor receptor 2 (sHER2). HER2 is a 185-kDa protein arising from the intracellular, transmembrane and extracellular domains (ECD) (51). The ECD is occasionally spliced by metalloprotease, resulting in the release of sHER2 into the peripheral circulation (52). sHER2 is an important biomarker for breast cancer treated with cyclophosphamide, methotrexate and fluorouracil therapy in combination with epirubicin (HR=0.80; 95% CI=0.68‑0.95; P=0.009) (50).

Methylated paired-like homeodomain 2 (PITX2P2). C-phosphate-G islands located within the gene regulatory site are associated with the suppression of gene expression. The methylation of DNA dinucleotides in this gene is a common early event subsequent to the onset of cancer (58-60). Methylation patterns specific to tumor subtypes, including breast cancer, are reportedly associated with clinical outcomes (61-63). Several studies reported that PITX2 DNA methylation was associated with a high risk of relapse in lymph node metastasis-positive, hormone receptor-positive breast cancer patients undergoing whole body adjuvant tamoxifen therapy (64,65). In a cohort

Table II. List of biomarkers that presented <2 risk ratios compared to the control populations (low and moderate reliable markers).

<table>
<thead>
<tr>
<th>Authors</th>
<th>Biomarker</th>
<th>Endpoint</th>
<th>Condition</th>
<th>HR</th>
<th>95% CI</th>
<th>No.</th>
<th>Sample</th>
<th>Periods</th>
<th>(Ref.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jézéquel et al</td>
<td>FTL</td>
<td>MFS</td>
<td>&lt;2.4</td>
<td>1.0</td>
<td>-</td>
<td>198</td>
<td>Biopsy</td>
<td>1980-2000</td>
<td>(40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&gt;2.4</td>
<td>1.3</td>
<td>1.10-1.50 (P=0.001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harbeck et al</td>
<td>uPA/PAI-1</td>
<td>DFS</td>
<td>Low</td>
<td>1.0</td>
<td>-</td>
<td>409</td>
<td>Blood</td>
<td>1993-1998</td>
<td>(43)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>1.84</td>
<td>1.1-3.0 (P=0.017)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OS</td>
<td>Low</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>1.85</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Villaseñor et al</td>
<td>CRP</td>
<td>OS</td>
<td>&lt;1 mg/l</td>
<td>1.0</td>
<td>-</td>
<td>2,919</td>
<td>Blood</td>
<td>1995-2000</td>
<td>(46)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥10 mg/l</td>
<td>1.96</td>
<td>1.22-3.13 (P&lt;0.001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Earl et al</td>
<td>Ch17CEP</td>
<td>OS</td>
<td>Normal</td>
<td>1.0</td>
<td>-</td>
<td>1,762</td>
<td>Biopsy</td>
<td>1996-2001</td>
<td>(50)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Duplicated</td>
<td>0.80</td>
<td>0.68-0.95 (P=0.009)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moreno-Aspitia et al</td>
<td>sHER2</td>
<td>DFS</td>
<td>&lt;15</td>
<td>1.0</td>
<td>-</td>
<td>2,318</td>
<td>Blood</td>
<td>2004-2005</td>
<td>(55)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥15</td>
<td>2.36</td>
<td>1.19-4.70 (P=0.01)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sun et al</td>
<td>MAD1L1</td>
<td>OS</td>
<td>Low</td>
<td>1.0</td>
<td>-</td>
<td>461</td>
<td>Biopsy</td>
<td>2006</td>
<td>(57)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High</td>
<td>1.825</td>
<td>(P=0.027)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hartmann et al</td>
<td>PITX2P2</td>
<td>TDM</td>
<td>Normal</td>
<td>1.0</td>
<td>-</td>
<td>241</td>
<td>Biopsy</td>
<td>NA</td>
<td>(66)</td>
</tr>
<tr>
<td></td>
<td>Methylation</td>
<td></td>
<td>Duplicated</td>
<td>1.66</td>
<td>1.21-2.28 (P=0.002)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MFS, metastasis-free survival; uPA/PAI-1, urokinase-type plasminogen activator and plasminogen activator type 1 inhibitor; CRP, C-reactive protein; Ch17CEP, Chromosome 17 centromere enumeration probe; sHER2, soluble human epidermal growth factor receptor 2; MAD1L1, mitotic arrest deficient like 1; PITX2P2, methylation of paired-like homeodomain 2; TDM, time to distant metastasis; DFS, disease free survival; OS, overall survival.
study of 241 lymph node metastasis-positive breast cancer patients with a history of anthracycline treatment, PITX2P2 methylation (a subtype of PITX2 methylation) was associated with an increased long-term relapse (HR=1.66; 95% CI=1.21-2.28; P=0.002) and reduced survival rates (HR=1.47; 95% CI=1.11-1.96; P=0.0084) (66).

5. Conclusions

In the present review of studies between 2009 and 2014, biomarkers were grouped according to reliability (high, medium, or low). A total of 3 studies were retrieved from the literature that classified Ki-67 as a high reliability biomarker. The utility of Ki-67 as a biomarker has been re-evaluated in the present study.

Of the high reliability biomarkers referred to in the 9 studies included in the present review, 0 were assessed by bioassays and only 1 mentioned biomarker measurement in peripheral blood. Although the evaluation of proteins in peripheral blood is relatively simple, in 2013, Johansson (7) reported that the identification of biomarkers is difficult, as measurements of biomarkers require too much quantification data. Therefore, the development of biomarkers from peripheral blood presents a challenge for future studies.

Although a number of molecules were identified in the present review, other markers, such as hormone receptors, were not widely evaluated. The ratio of ER-α/ER-β expression, β IIII-tubulin and thyroid-stimulating hormone were identified as oncological indicators in breast cancer. Thus, additional studies of the correlations between the aforementioned biomarkers and prognosis and treatment response may be useful.

This study hypothesizes that the most important biomarkers of breast cancer are found in the blood, and that RARA, uPA/PAI-1, CRP, shHER2 are good biomarkers in routine examination. The authors highlight RARA in particular as an important biomarker in breast cancer. Future studies on biomarkers are likely to progress the understanding of the topic. For all biomarkers, reliability is important, but for the development of useful biomarkers, cost and ease of monitoring are crucial considerations.

Acknowledgements

The authors would like to thank Drs. Tousei Ohmura, Hidekazu Kameshima, and Yasuyo Suzuki for their help with preparing this study and participating in valuable discussions. The present study was partially supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (grant nos. 26461921, 25293289, 24659592 and 50175634).

References


58. Baylin SB and Herman JG: DNA hypermethylation in tumorigen-
2463-2467, 1996.
60. Herman JG and Baylin SB: Gene silencing in cancer in asso-
ciation with promoter hypermethylation. N Engl J Med 349:
61. Frühwald MC: DNA methylation patterns in cancer: Novel prog-
62. Laird PW: The power and the promise of DNA methylation
63. Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, 
Böhlmann I, Paradiso A, Spyropoulos F, Thomssen C, Mueller V, 
Nährig J, et al: DNA-methylation of the homeodomain tran-
scription factor PITX2 reliably predicts risk of distant disease 
recurrence in tamoxifen-treated, node-negative breast cancer 
patients-Technical and clinical validation in a multi-centre setting 
in collaboration with the European Organisation for Research 
and Treatment of Cancer (EORTC) PathoBiology group. Eur J 
64. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, 
Model F, Kluth A, Bolt-de Vries J, Siewerts AM, 
Portengen H, et al: Association of DNA methylation of phospho-
sine aminotransferase with response to endocrine therapy in 
patients with recurrent breast cancer. Cancer Res 65: 4101-4117, 
2005.
65. Widschwendter M, Siegmund KD, Müller HM, Fieg H, Marth C, 
Müller-Holzner E, Jones PA and Laird PW: Association of 
breast cancer DNA methylation profiles with hormone receptor 
status and response to tamoxifen. Cancer Res 64: 3807-3813, 
2004.
66. Hartmann O, Spyroatos F, Harbeck N, Dietrich D, Fassbender A, 
Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, 
outcome in node-positive, estrogen receptor-positive breast 
cancer with adjuvant anthracycline-based chemotherapy. Clin 